C-TASC hires senior statistician

C-TASC hires senior statistician

Sandra Forman Brings Two Multi-Center Clinical Trials to Clinical Trials Solutions Firm

BALTIMORE - June 23, 2010 - Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, announced today it has hired Sandra Forman as a senior statistician. Ms. Forman joins C-TASC's team of PhD and MS biostatisticians which offers statistical consulting, regulatory advice, monitoring services, biorepository management and data management services to government, university and private research organizations that are conducting clinical trials.

Ms. Forman is currently principal investigator (PI) of two multi-center clinical trials that she is bringing to C-TASC. In the first trial, C-TASC will be performing data analysis of the long-term results of a National Heart, Lung and Blood Institute (NHLBI) study comparing conventional medical therapy and percutaneous coronary intervention plus medical therapy in patients with an occluded artery. The original results of the study were published in the New England Medical Journal in December 2006 and the long-term follow up results are expected to be presented at the American Heart Association in November 2010.

In the second trial, C-TASC will serve as the Randomization and Statistical Analysis Center for a Johns Hopkins University study that will determine if percutaneous coronary intervention can be performed safely and effectively at hospitals without on-site cardiac surgery. So far, the study has enrolled 15,000 patients and expects to enroll a total of 18,000.

Ms. Forman joins C-TASC from the Maryland Medical Research Institute in Baltimore, where she has worked as a statistician since 1979. In that time she has served as statistician, study manager or principal investigator on more than 25 clinical trials and has co-authored 86 articles printed in peer-reviewed journals. She previously worked for C-TASC on a part-time basis from 1990-2002.

For 20 years, C-TASC has specialized in supporting best practices management of clinical trials and studies for government, university and private organizations. The company has grown rapidly in the last three years, nearly doubling its revenue and number of employees since 2007. In that time, it has added professional consultation in all areas of clinical trial management to its offered services, incorporated a proprietary Web-based software system for clinical trials management and developed a relationship with the Food and Drug Administration to convert legacy data into the new standard Study Data Tabulation Model (SDTM) format.

"We are happy to welcome Sandra back to C-TASC, this time in a full-time role," said Dr. Bruce Thompson, president of C-TASC. "She has more than 30 years of experience working in clinical trials for many of our area's major research institutions, and I am certain she will be a valuable addition to our statistician team."

"I am excited to return to C-TASC and re-join many friends and former colleagues," said Ms. Forman. "C-TASC is a fast-growing company and I am happy to be a part of such an invigorating environment."

About C-TASC Based near Baltimore, Clinical Trials & Surveys Corp. (C-TASC) is a clinical trials solutions company that has supported best practices management of clinical trials and studies for government, university and private organizations since 1989. C-TASC has a successful research history in cancer, cardiovascular disease, AIDS, pulmonary disease, Cystic Fibrosis, sleep disorders and pharmaco-epidemiology. C-TASC's software group utilizes the firm's StudyCTMSTM product suite to provide investigators with complete Web-based trial management designed to deliver FDA-acceptable data. The C-TASC professional services group provides expert consultation in all areas of clinical trial management including medical and statistical study design, project management, data conversion including FDA SDTM formatting, performance monitoring, data quality control and analysis as well as support for study publication and presentation. For more information about C-TASC's projects, products and services, please visit www.c-tasc.com.

Suggested Articles

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

VBL got the green light after the committee looked at unblinded overall survival data for the second pre-planned interim analysis.

Eleusis researchers discovered that structural characteristics of the 2C-H class of psychedelics help to control asthma without behavioral effects.